Skip to content
ANAVEX
ANAVEXANAVEX
  • HOME
  • ABOUT US
  • OUR TEAM
  • NEWS
  • INVESTORS
    • Events
    • Share Data
    • Analyst Coverage
    • Code of Conduct
    • Investor Material
    • Presentations
  • JOIN US
Search
  • HOME
  • ABOUT US
  • OUR TEAM
  • NEWS
  • INVESTORS
    • Events
    • Share Data
    • Analyst Coverage
    • Code of Conduct
    • Investor Material
    • Presentations
  • JOIN US
View allAlzheimer's DiseaseAnavex2-73EventsNews ReleasesPIPELINEPressUncategorized

Anavex Life Sciences Receives Approval To Initiate Phase 2b/3 Clinical Trial of ANAVEX®2-73 for the Treatment of Early Alzheimer’s Disease

Anavex Life Sciences Reports Fiscal Second Quarter 2018 Financial Results

Anavex Life Sciences to Announce Fiscal Second Quarter 2018 Financial Results on Thursday, May 10, 2018

Anavex Life Sciences to Initiate Phase 2 Study of ANAVEX®2-73 in Parkinson’s Disease Dementia and Provides Clinical Study Update for ANAVEX®2-73 in Rett Syndrome

Anavex Life Sciences to Present at the 30th Annual ROTH Conference

Anavex Life Sciences to Present New Preclinical Data at the 20th Annual Meeting of the American Society for Experimental Neurotherapeutics (ASENT)

Anavex Life Sciences to Present at Cowen and Company 38th Annual Health Care Conference

Anavex

Anavex Life Sciences Strengthens Management Team and Board of Directors

Anavex Life Sciences to Present at the 2018 BIO CEO & Investor Conference

Anavex Life Sciences Provides Clinical Programs Update and Reports Fiscal First Quarter 2018 Financial Results

123456…
7891011121314151617181920212223242526
27
ANAVEX

ANAVEX® is a trademark of Anavex®Life Sciences Corp. - 2019 All Rights Reserved

Go to Top